Milton C. Weinstein

Henry J. Kaiser Professor of Health Policy and Management
Health Policy and Management
Harvard School of Public Health

Professor of Medicine
Harvard Medical School
Academic Director, CHDS
Home page:


Milton C. Weinstein, Ph.D., is the Henry J. Kaiser Professor of Health Policy and Management and Professor of Biostatistics at the Harvard School of Public Health and Professor of Medicine at the Harvard Medical School.  At the Harvard School of Public Health he is Academic Director of the Center for Health Decision Science.  He is best known for his research on cost-effectiveness of medical practices and for developing methods of economic evaluation and decision analysis in health care.  He is a co-developer of the CEPAC (Cost-Effectiveness of Preventing AIDS Complications) computer simulation model, and has conducted studies on prevention and treatment of HIV infections.  He was the co-developer of the Coronary Heart Disease Policy Model, which has been used to evaluate the cost-effectiveness of cardiovascular prevention and treatment.  He is an author of four books: Decision Making in Health and Medicine: Integrating Evidence and Values; Cost-Effectiveness in Health and Medicine, the report of the Panel of Cost Effectiveness in Health and Medicine; Clinical Decision Analysis; and Hypertension: A Policy Perspective.  He has also published more than 300 papers in peer-reviewed medical, public health, and economics journals.  He consults with industry and government and is a Principal Consultant with Optuminsight.  He is an elected member of the Institute of Medicine of the National Academy of Sciences, and a recipient of the Award for Career Achievement from the Society for Medical Decision Making and the Avedis Donabedian Lifetime Achievement Award from the International society for Pharmacoeconomics and Outcomes Research.  Dr. Weinstein received his A.B. and A.M. in Applied Mathematics (1970), his M.P.P. (1972), and his Ph.D. in Public Policy (1973) from Harvard University.

Key Publications:
Posted on February 1, 2010
Authors: Gaziano Thomas A, Opie Lionel H, Weinstein Milton C
Lancet 2006 368(9536): 679-686  PubmedID: 239849000000   ISSN/ISBN: 0140-6736
Background Cardiovascular disease is the leading cause of death, with 80% of cases occurring in developing countries. We therefore aimed to establish whether use of evidence-based multidrug regimens for patients at high risk for cardiovascular diseas... (more »)
Posted on February 1, 2010
Authors: Weinstein MC, Toy EL, Sandberg EA, Neumann PJ, Evans JS, Kuntz KM, Graham JD, Hammitt JK
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2001 4(5): 348-361  PubmedID: 11705125   ISSN/ISBN: 1098-3015
The role of models to support recommendations on the cost-effective use of medical technologies and pharmaceuticals is controversial. At the heart of the controversy is the degree to which experimental or other empirical evidence should be required p... (more »)
All Publications:
Posted on March 21, 2012
Authors: Tosteson AN, Tosteson TD, Lurie JD, Abdu W, Herkowitz H, Andersson G, Albert T, Bridwell K, Zhao W, Grove MR, Weinstein M, Weinstein JN
Spine (Phila Pa 1976) 201` 36(24): 2061-8  DOI: 10.1097/BRS.0b013e318235457b

STUDY DESIGN:

Cost-effectiveness analysis of a randomized plus observational cohort trial.

OBJECTIVE:

Analyze cost-effectiveness of Spine Patient Outcomes Research Trial data over 4 years comparing surgery with nonoperat... (more »)

Posted on January 21, 2013
Authors: Walensky RP, Sax PE, Nakamura YM, Weinstein M, Pei PP, Freedburg KA, Paltiel AD, Schackman BR
Ann Intern Med 2013 158(2): 84-92  DOI: 10.7326/0003-4819-158-2-201301150-00002

U.S. HIV treatment guidelines recommend branded once-daily, 1-pill efavirenz-emtricitabine-tenofovir as first-line antiretroviral therapy (ART). With the anticipated approval of generic efavirenz in the United States, a once-daily, 3-pill alternat... (more »)

Posted on October 19, 2013
Authors: Pandya A, Gaziano TA, Weinstein M, Cutler D
Health Aff (Millwood) 2013 32(10): 1706-14

In the past several decades, some risk factors for cardiovascular disease have improved, while others have worsened. For example, smoking rates have dropped and treatment rates for cardiovascular disease have increased-factors that have made the d... (more »)

Posted on January 6, 2012
Authors: O'Sullivan AK, Weinstein M, Pandya A, Thompson D, Langston AA, Perfect JR, Papadopoulos G
Am J Health Syst Pharm 2012 69(2): 149-56  PubmedID: 22215361   DOI: 10.2146/ajhp110149

Purpose The results of a pharmacoeconomic study of the cost-effectiveness of posaconazole versus fluco... (more »)

Posted on May 14, 2012
Authors: O'Sullivan AK, Weinstein M, Pandya A, Thompson D, Langston AA, Perfect JR, Papadopoulos G
Am J Health Syst Pharm 2012 69(2): 149-56  PubmedID: 22215361   DOI: 10.2146/ajhp110149

PURPOSE:

The results of a pharmacoeconomic study of the cost-effectiveness of posaconazole versus fluconazole in preventing invasive fungal infections (IFIs) in patients with graft-versus-host diseasemore »)

Posted on October 3, 2012
Authors: Briggs AH, Weinstein M, Fenwick EA, Karnon J, Sculper MJ, Paltiel AD
Value Health. 2012 15(6): 835-42  DOI: 10.1016/j.jval.2012.04.014

A model's purpose is to inform medical decisions and health care resource allocation. Modelers employ quantitative metho... (more »)

Posted on October 3, 2012
Authors: Kimmel A, Resch SC, Anglaret X, Daniels N, Goldie S, Danel C, Wong AY, Freedberg K, Weinstein M
Cost Eff Resour Alloc 2012 10(1)  DOI: 10.1186/1478-7547-10-12

BACKGROUND: In resource-limited settings, HIV budgets are flattening or decreasing. A policy of discontinu... (more »)

Posted on October 3, 2012
Authors: Lorenzana SB, Hughes MD, Grinsztejn B, Collier AC, Luz PM, Freedberg K, Wood R, Levison JH, Mugyenyi PN, Salata R, Wallis CL, Weinstein M, Schooley RT, Walensky RP
AIDS 2012 26(9): 1083-93  DOI: 10.1097/QAD.0b013e32835221eb

To project the clinical and economic outcomes of a genotype assay for selection of third-line antiretrovir... (more »)

Posted on October 22, 2012
Authors: Taylor DC, Pawar V, Kruzikas DT, Gilmore KE, Sanon M, Weinstein M
Pharmacoeconomics 2012 30(2): 119-26  DOI: 10.2165/11593360-000000000-00000

The aim of this study was to examine how calibration uncertainty affects the overall uncertainty of a math... (more »)

Posted on January 13, 2011
Authors: Ladapo JA, Jaffer FA, Weinstein M, Froelicher ES
Archives of Internal Medicine 2011 171(1): 39-45  PubmedID: 21220659

BACKGROUND: As many as 70% of smokers with acute myocardial infarction (AMI) continue to smoke after hospital discharge despite high rates of inpatient smoking cessation counseling. Supportive contact after discharge improves... (more »)

Posted on June 10, 2011
PLoS One 2011 6(5)  PubmedID: 21655241

BACKGROUND:

National and international primary CVD risk screening guidelines focus on using total CVD risk scores. Recently, we developed a non-laboratory-based CVD risk score (inputs: age, sex, smoking, diabetes, systolic blood pre... (more »)

Posted on August 16, 2011
Authors: Taylor DC, Pawar V, Kruzikas D, Gilmore KE, Pandya A, Iskandar R, Weinstein M
Value Health 2011 14(5): 700-4  PubmedID: 21839408

OBJECTIVES:

To assess the impact of simulating temporal changes in health-care practice patterns when calibrating longitudinal models to cross-sectional data.

METHODS:

A Markov model of cervical cancer was calibrated to... (more »)

Posted on September 6, 2011
Authors: McMahon PM, Kong CY, Bouzan C, Weinstein M, Cipriano LE, Tramontano AC, Johnson BE, Weeks JC, Gazelle G
J Thorac Oncol 2011  PubmedID: 21892105

INTRODUCTION:

A randomized trial has demonstrated that lung cancer screening reduces mortality. Identifying participant and program characteristics that influence the cost-effectiveness of screening will help translate trial results in... (more »)

Posted on October 11, 2011
Authors: Taylor DC, Pawar V, Kruzikas D, Gilmore KE, Pandya A, Iskandar R, Weinstein M
Value Health 2011 14(5): 700-4  PubmedID: 21839408

OBJECTIVES:

To assess the impact of simulating temporal changes in health-care practice patterns when calibrating longitudinal models to cross-sectional data.

METHODS:

A Markov model of cervical cancer was calibrated to... (more »)

Posted on November 4, 2011
Authors: Tosteson AN, Tosteson TD, Lurie JD, Abdu W, Herkowitz H, Andersson G, Albert T, Bridwell K, Zhao W, Grove MR, Weinstein M, Weinstein J
Spine 2011 36(24)  PubmedID: 22048651

STUDY DESIGN.: Cost-effectiveness analysis of a randomized plus observational cohort trial. OBJECTIVE.: Analyze cost-effectiveness of Spine Patient Outcomes Research Trial data over 4 years comparing surgery with nonoperative care for three com... (more »)

Instructor:
Milton Weinstein
Term:
Summer
An introductory course in decision analysis methods relevant to clinical decision making and clinical research. Topics range from Bayes theorem and evaluation of diagnostic test strategies to cost-effectiveness analysis in clinical research and health policy.

Global HIV/AIDS Policy Modeling

Identifying the most effective treatment strategies for HIV infection in less developed countries

Predicting Cardiovascular Disease Risk in India and South Africa

Evaluating strategies for assessing cardiovascular risk

HIV/AIDS Policy Modeling for the U.S.

Addressing critical HIV/AIDS-related clinical and policy questions within the U.S.

Cardiovascular Disease Policy Model

A model focused on screening, prevention and treatment of CVD

Medical Spending and Health Outcomes

Should the U.S. be using cost effectiveness analysis with regards to medical expenditures?